Shanghai dismisses two scientists over child's death in gene-editing trial
Shanghai authorities have dismissed two researchers and barred them for five years after an investigation into the death of a child who received an experimental gene-editing treatment, Sixth Tone reported. The inquiry found the death was left out of a Nature paper and that researchers had undisclosed financial ties to the family.

The investigation findings were released on November 13, according to Sixth Tone. Qiu Zilong, the neuroscientist whose team ran the work, and Yang Kan, the paper's first and corresponding author, were dismissed and banned for five years. The trial's lead investigator, surnamed Yu, was demoted. The head of the hospital's ethics office, surnamed Shi, was removed and demoted. Xinhua Hospital, affiliated with Shanghai Jiao Tong University, received an administrative penalty whose details were not disclosed.
The child had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder with no effective treatment. The treatment was given on March 24, 2025, and the child died seven days later. At an emergency review on April 2, the hospital's ethics committee attributed the death to thrombotic microangiopathy, a complication of gene therapy, and ordered the study ended.
Investigators found that the death was not mentioned in a February 2026 paper in Nature from Qiu's team. They found no data fabrication, but reported discrepancies between the methods described in the paper and those actually used. They also found that the family had contributed 5.3 million yuan (about $800,000) to the research and separately gave researchers about 1.06 million yuan in money and gifts. Four researchers had undisclosed financial conflicts of interest.
The case became public in July, when Science and Retraction Watch published a joint investigation. Shanghai Jiao Tong University had said it set up a working group to review the trial and the paper. Nature added an editor's note to the paper on July 29, and the paper has not been retracted, according to earlier reports.
The Shanghai Municipal Health Commission said it would soon begin special inspections of clinical research involving emerging biomedical technologies. The investigation said research institutions must recognise the high risks of clinical studies of new treatments. Xinhua Hospital had been fined about 24,000 yuan ($3,500) by local health authorities in September 2025, earlier reporting said.



